Loss of CBP causes T cell lymphomagenesis in synergy with p27 Kip1 insufficiency

Cancer Cell

Volumn 5, Issue 2, 2004, Pages 177-189

  Kang Decker, Ningling ^a   Tong, Caili ^a   Boussouar, Fayçal ^c   Baker, Darren J ^a   Xu, Wu ^c   Leontovich, Alexey A ^b   Taylor, William R ^b   Brindle, Paul K ^c   Van Deursen, Jan M A ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; HISTONE ACETYLTRANSFERASE PCAF; PROTEIN P27; PROTEIN P53; PROTEIN SUBUNIT; S PHASE KINASE ASSOCIATED PROTEIN 2; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DATA ANALYSIS; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; T CELL LYMPHOMA; THYMOCYTE; TRANSACTIVATION; UPREGULATION;

ANIMALIA;

EID: 1442285891     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00022-4     Document Type: Article

References (50)

1. Alkema M.J., Bronk M., Verhoeven E., Otte A., van't Veer L.J., Berns A., van Lohuizen M. Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev. 11:1997;226-240.
2. Avantaggiati M.L., Ogryzko V., Gardner K., Giordano A., Levine A.S., Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 89:1997;1175-1184.
3. Blain S.W., Scher H.I., Cordon-Cardo C., Koff A. p27 as a target for cancer therapeutics. Cancer Cell. 3:2003;111-115.
4. Blobel G.A. CREB-binding protein and p300. Molecular integrators of hematopoietic transcription Blood. 95:2000;745-755.
5. Bloom J., Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin. Cancer Biol. 13:2003;41-47.
6. Carrano A.C., Eytan E., Hershko A., Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1:1999;193-199.
7. Catzavelos C., Bhattacharya N., Ung Y.C., Wilson J.A., Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L.et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein. prognostic implications in primary breast cancer Nat. Med. 3:1997;227-230.
8. Chervinsky D.S., Zhao X.F., Lam D.H., Ellsworth M., Gross K.W., Aplan P.D. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice. parallels with E2A-deficient mice Mol. Cell. Biol. 19:1999;5025-5035.
9. Deguchi K., Ayton P.M., Carapeti M., Kutok J.L., Snyder C.S., Williams I.R., Cross N.C., Glass C.K., Cleary M.L., Gilliland D.G. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell. 3:2003;259-271.
10. Erlanson M., Portin C., Linderholm B., Lindh J., Roos G., Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood. 92:1998;770-777.
11. Fero M.L., Rivkin M., Tasch M., Porter P., Carow C.E., Firpo E., Polyak K., Tsai L.H., Broudy V., Perlmutter R.M.et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 85:1996;733-744.
12. Fero M.L., Randel E., Gurley K.E., Roberts J.M., Kemp C.J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 396:1998;177-180.
13. Fowlkes B.J., Robey E.A. A reassessment of the effect of activated Notch1 on CD4 and CD8 T cell development. J. Immunol. 169:2002;1817-1821.
14. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Chin S.F., Daigo Y., Russell P., Wilson A., Sowter H.M.et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24:2000;300-303.
15. Giordano A., Avantaggiati M.L. p300 and CBP. Partners for life and death J. Cell. Physiol. 181:1999;218-230.
16. Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14:2000;1553-1577.
17. Grossman S.R. p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 268:2001;2773-2778.
18. Gu W., Shi X.L., Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature. 387:1997;819-823.
19. Haupt Y., Bath M.L., Harris A.W., Adams J.M. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene. 8:1993;3161-3164.
20. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., Yao T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20:2001;1331-1340.
21. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1994;1-7.
22. Jacobs J.J., Scheijen B., Voncken J.W., Kieboom K., Berns A., van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13:1999;2678-2690.
23. Kasper L.H., Brindle P.K., Schnabel C.A., Pritchard C.E., Cleary M.L., van Deursen J.M. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol. Cell. Biol. 19:1999;764-776.
24. Kasper L.H., Boussouar F., Ney P.A., Jackson C.W., Rehg J., van Deursen J.M., Brindle P.K. A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature. 419:2002;738-743.
25. Kee B.L., Arias J., Montminy M.R. Adaptor-mediated recruitment of RNA polymerase II to a signal-dependent activator. J. Biol. Chem. 271:1996;2373-2375.
26. Kemp C.J., Wheldon T., Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet. 8:1994;66-69.
27. Kung A.L., Rebel V.I., Bronson R.T., Ch'ng L.E., Sieff C.A., Livingston D.M., Yao T.P. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 14:2000;272-277.
28. Latres E., Chiarle R., Schulman B.A., Pavletich N.P., Pellicer A., Inghirami G., Pagano M. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl. Acad. Sci. USA. 98:2001;2515-2520.
29. Li M., Luo J., Brooks C.L., Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277:2002;50607-50611.
30. Lill N.L., Grossman S.R., Ginsberg D., DeCaprio J., Livingston D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature. 387:1997;823-827.
31. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., Berger S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 19:1999;1202-1209.
32. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., Jessup J.M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3:1997;231-234.
33. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
34. Lu, Q., Hutchins, A.E., Doyle, C.M., Lundblad, J.R., and Kwok, R.P. (2003). Acetylation of cAMP-responsive element-binding protein (CREB) by CREB-binding protein enhances CREB-dependent transcription. J. Biol. Chem. Published online February 20, 2003. 10.1074/jbc.M300546200.
35. Martins C.P., Berns A. Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J. 21:2002;3739-3748.
36. Muhua L., Adames N.R., Murphy M.D., Shields C.R., Cooper J.A. A cytokinesis checkpoint requiring the yeast homologue of an APC- binding protein. Nature. 393:1998;487-491.
37. Muller D., Bouchard C., Rudolph B., Steiner P., Stuckmann I., Saffrich R., Ansorge W., Huttner W., Eilers M. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene. 15:1997;2561-2576.
38. Nakajima T., Uchida C., Anderson S.F., Lee C.G., Hurwitz J., Parvin J.D., Montminy M. RNA helicase A mediates association of CBP with RNA polymerase II. Cell. 90:1997;1107-1112.
39. O'Hagan R.C., Ohh M., David G., de Alboran I.M., Alt F.W., Kaelin W.G. Jr., DePinho R.A. Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev. 14:2000;2185-2191.
40. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 87:1996;953-959.
41. Oike Y., Takakura N., Hata A., Kaname T., Akizuki M., Yamaguchi Y., Yasue H., Araki K., Yamamura K., Suda T. Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. Blood. 93:1999;2771-2779.
42. Ozdag H., Batley S.J., Forsti A., Iyer N.G., Daigo Y., Boutell J., Arends M.J., Ponder B.A., Kouzarides T., Caldas C. Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. Br. J. Cancer. 87:2002;1162-1165.
43. Petrij F., Giles R.H., Dauwerse H.G., Saris J.J., Hennekam R.C., Masuno M., Tommerup N., van Ommen G.J., Goodman R.H., Peters D.J.et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature. 376:1995;348-351.
44. Porter P.L., Malone K.E., Heagerty P.J., Alexander G.M., Gatti L.A., Firpo E.J., Daling J.R., Roberts J.M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:1997;222-225.
45. Rebel V.I., Kung A.L., Tanner E.A., Yang H., Bronson R.T., Livingston D.M. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc. Natl. Acad. Sci. USA. 99:2002;14789-14794.
46. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:1998;2831-2841.
47. Stegall M., Park W., Kim D., Kremers W. Gene expression during acute allograft rejection. Novel statistical analysis of microarray data Am. J. Transplant. 2:2002;913-925.
48. Wagner K.U., Wall R.J., St-Onge L., Gruss P., Wynshaw-Boris A., Garrett L., Li M., Furth P.A., Hennighausen L. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res. 25:1997;4323-4330.
49. Yang W., Shen J., Wu M., Arsura M., FitzGerald M., Suldan Z., Kim D.W., Hofmann C.S., Pianetti S., Romieu-Mourez R.et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 20:2001;1688-1702.
50. Yao T.P., Oh S.P., Fuchs M., Zhou N.D., Ch'ng L.E., Newsome D., Bronson R.T., Li E., Livingston D.M., Eckner R. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell. 93:1998;361-372.